4-(propan-2-ylidene)piperidine | 854904-29-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(propan-2-ylidene)piperidine
• 英文别名: 4-(1-Methylethylidene)piperidine；4-propan-2-ylidenepiperidine
• CAS: 854904-29-3
• 化学式: C₈H₁₅N
• mdl: MFCD13176201
• 分子量: 125.214
• InChiKey: SRYVUMHANHOENO-UHFFFAOYSA-N

物化性质

• 沸点：
  167.2±9.0 °C(Predicted)
• 密度：
  0.867±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  4-(propan-2-ylidene)piperidine 、 4-[[2-[methyl(methylsulfonyl)amino]benzoyl]amino]benzenesulfonyl chloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以84 %的产率得到2-(N-methylmethylsulfonamido)-N-(4-((4-(propan-2-ylidene)piperidin-1-yl)sulfonyl)phenyl)benzamide
  参考文献：
  名称：

  [EN] LPXH INHIBITORS AS ANTI-INFECTIVE AGENTS
  [FR] INHIBITEURS DE LPXH EN TANT QU'AGENTS ANTI-INFECTIEUX

  摘要：

  The present invention relates to compounds of formula (IIIa), which are suitable for use as anti-infectives, particularly as antibiotics. X1is N or CH. …. is a single or a double bond. When …. is a single bond then X2is selected from the group consisting of CH, N, and N(O), and Y is selected from the group consisting of optionally substituted C3-C10alkyl, optionally substituted C3-C8cycloalkyl, optionally substituted phenyl, and optionally substituted 6-membered heteroaryl. When …. is a double bond then X2is C, and, and Y is selected from the group consisting of optionally substituted C3-C10alkylidene, and optionally substituted C3-C8cycloalkylidene. E is CH, C-OMe or N. Each instance of Z2is independently selected from CH, CF and N. The invention further relates to the use of such compounds in therapeutic applications, as well as pharmaceutical composition comprising such compounds.

  公开号：

  WO2022220725A1
• 作为产物：
  描述：

  4-isopropyl-1,2,3,6-tetrahydro-pyridine 在 4-(α-bromo-isopropyl)-piperidine; hydrobromide 、 silver(l) oxide 作用下， 生成 4-(propan-2-ylidene)piperidine
  参考文献：
  名称：

  11.尝试制备7-取代的双环[1：2：2] -1-氮杂庚烷

  摘要：

  DOI：

  10.1039/jr9410000041

文献信息

• PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
  申请人：Bristol-Myers Squibb Company

  公开号：US20150232463A1

  公开（公告）日：2015-08-20

  The disclosure generally relates to compounds of formula I, II, III and IV, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

  该披露通常涉及公式I、II、III和IV的化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。该披露提供了HIV的新型抑制剂，包含这些化合物的药物组合物，以及在治疗HIV感染中使用这些化合物的方法。
• [EN] PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] DÉRIVÉS DE L'ACIDE PYRIDIN-3-YL-ACÉTIQUE UTILISÉS COMME INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：VIIV HEALTHCARE UK (NO 5) LTD

  公开号：WO2017006281A1

  公开（公告）日：2017-01-12

  Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. (I)

  公开的是Formula I的化合物，包括药用可接受的盐，含有这些化合物的药物组合物，制备这些化合物的方法以及它们在抑制HIV整合酶和治疗感染HIV或艾滋病的人中的用途。
• PHOSPHODIESTERASE 10 INHIBITORS
  申请人：Hu Essa

  公开号：US20090062277A1

  公开（公告）日：2009-03-05

  The present invention is directed to certain compounds useful as phosphodiesterase 10 (PDE10) inhibitors that have the formula where R 1 , R 2 , R 3 , R 4 , X, Y and Z are as defined herein, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  本发明涉及一些化合物，这些化合物可用作磷酸二酯酶10（PDE10）抑制剂，其具有以下结构式：其中R1、R2、R3、R4、X、Y和Z如本文所定义，包含这些化合物的药物组合物以及制备这些化合物的方法。该发明还涉及治疗由PDE10介导的疾病的方法，如肥胖、非胰岛素依赖性糖尿病、精神分裂症、躁郁症、强迫症等。
• [EN] TARGETED THERAPEUTICS<br/>[FR] AGENTS THÉRAPEUTIQUES CIBLES
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2015116774A1

  公开（公告）日：2015-08-06

  The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

  本发明提供了药理化合物，包括一个效应因子结合到一个结合因子上，该结合因子将效应因子定向到感兴趣的生物靶点。同样，本发明提供了包括该化合物的组合物、试剂盒和方法（例如治疗、诊断和成像）。该化合物可以描述为蛋白质相互作用结合基因药物偶联物（SDC-TRAP）化合物，其中包括一个蛋白质相互作用结合基因和一个效应因子。例如，在治疗癌症的某些实施例中，SDC-TRAP可以包括一种Hsp90抑制剂结合到细胞毒性剂作为效应因子。
• Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US09193720B2

  公开（公告）日：2015-11-24

  The disclosure generally relates to compounds of formula I, II, III and IV, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

  本公开涉及I、II、III和IV式化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。本公开提供了HIV的新型抑制剂，含有这些化合物的制药组合物以及使用这些化合物治疗HIV感染的方法。